Δ9-THC reduces reward-related brain activity in healthy adults

Rationale Greater availability of cannabis in the USA has raised concerns about adverse effects of the drug, including possible amotivational states. Lack of motivation may be assessed by examining acute effects of cannabinoids on reward processing. Objectives This study examined single doses of del...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Psychopharmacology 2022-09, Vol.239 (9), p.2829-2840
Hauptverfasser: Murray, Conor H., Glazer, James E., Lee, Royce, Nusslock, Robin, de Wit, Harriet
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 2840
container_issue 9
container_start_page 2829
container_title Psychopharmacology
container_volume 239
creator Murray, Conor H.
Glazer, James E.
Lee, Royce
Nusslock, Robin
de Wit, Harriet
description Rationale Greater availability of cannabis in the USA has raised concerns about adverse effects of the drug, including possible amotivational states. Lack of motivation may be assessed by examining acute effects of cannabinoids on reward processing. Objectives This study examined single doses of delta-9-tetrahydrocannabinol (∆9-THC; 7.5, 15 mg oral) in healthy adults using a version of the monetary incentive delay (MID) task adapted for electroencephalography (EEG; e-MID) in a within-subjects, double blind design. Methods Two phases of reward processing were examined: anticipation, which occurs with presentation of cues that indicate upcoming reward, punishment, or neutral conditions, and outcome, which occurs with feedback indicating hits or misses. During anticipation, we measured two event-related potential (ERP) components: the P300, which measures attention and motivation, and the LPP, which measures affective processing. During outcome processing, we measured P300 and LPP, as well as the RewP, which measures outcome evaluation. Results We found that ∆9-THC modulated outcome processing, but not reward anticipation. Specifically, both doses of ∆9-THC (7.5 and 15 mg) reduced RewP amplitudes after outcome feedback (hits and misses) relative to placebo. ∆9-THC (15 mg) also reduced P300 and LPP amplitudes following hits compared to misses, relative to both placebo and 7.5 mg ∆9-THC. Conclusions These findings suggest that ∆9-THC dampens responses to both reward and loss feedback, which may reflect an “amotivational” state. Future studies are needed to determine generalizability of this effect, such as its pharmacological specificity and its specificity to monetary vs other types of reward.
doi_str_mv 10.1007/s00213-022-06164-y
format Article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_10560585</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2703189566</sourcerecordid><originalsourceid>FETCH-LOGICAL-c431t-98e89b91183e8f69147c32e1d048b6ca843ed6e3e1341ebb16ba672404fad4463</originalsourceid><addsrcrecordid>eNp9kU1u2zAQhYkiRe38XKCLQEA23bCZISmKWgWBkSYFDGTjrglKGscyZMkhpQS6R86VM5WuU7fpotwMgfnmzRs8xj4jfEWA7DIACJQchOCgUSs-fmBTVFJwAZk4YlMAKbnE1EzYcQhriE8Z9YlNZKpR6FRN2dXrS84Xd7PEUzWUFGJ9dr7inhrXU5UU3tVt4sq-fqr7MYn_FbmmX42Jq4amD6fs49I1gc7e6gn78e1mMbvj8_vb77PrOS-VxJ7nhkxe5IhGklnqHFVWSkFYRUOFLp1RkipNklAqpKJAXTidCQVq6SqltDxhV3vd7VBsqCqp7b1r7NbXG-dH27navu-09co-dE8WIdWQmjQqfHlT8N3jQKG3mzqU1DSupW4IVmidpyBklkX04h903Q2-jfdZkYFEk6d6Z0nsqdJ3IXhaHtwg2F1Adh-QjQHZXwHZMQ6d_33HYeR3IhGQeyDEVvtA_s_u_8j-BHXCm6k</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2703189566</pqid></control><display><type>article</type><title>Δ9-THC reduces reward-related brain activity in healthy adults</title><source>MEDLINE</source><source>SpringerLink Journals - AutoHoldings</source><creator>Murray, Conor H. ; Glazer, James E. ; Lee, Royce ; Nusslock, Robin ; de Wit, Harriet</creator><creatorcontrib>Murray, Conor H. ; Glazer, James E. ; Lee, Royce ; Nusslock, Robin ; de Wit, Harriet</creatorcontrib><description>Rationale Greater availability of cannabis in the USA has raised concerns about adverse effects of the drug, including possible amotivational states. Lack of motivation may be assessed by examining acute effects of cannabinoids on reward processing. Objectives This study examined single doses of delta-9-tetrahydrocannabinol (∆9-THC; 7.5, 15 mg oral) in healthy adults using a version of the monetary incentive delay (MID) task adapted for electroencephalography (EEG; e-MID) in a within-subjects, double blind design. Methods Two phases of reward processing were examined: anticipation, which occurs with presentation of cues that indicate upcoming reward, punishment, or neutral conditions, and outcome, which occurs with feedback indicating hits or misses. During anticipation, we measured two event-related potential (ERP) components: the P300, which measures attention and motivation, and the LPP, which measures affective processing. During outcome processing, we measured P300 and LPP, as well as the RewP, which measures outcome evaluation. Results We found that ∆9-THC modulated outcome processing, but not reward anticipation. Specifically, both doses of ∆9-THC (7.5 and 15 mg) reduced RewP amplitudes after outcome feedback (hits and misses) relative to placebo. ∆9-THC (15 mg) also reduced P300 and LPP amplitudes following hits compared to misses, relative to both placebo and 7.5 mg ∆9-THC. Conclusions These findings suggest that ∆9-THC dampens responses to both reward and loss feedback, which may reflect an “amotivational” state. Future studies are needed to determine generalizability of this effect, such as its pharmacological specificity and its specificity to monetary vs other types of reward.</description><identifier>ISSN: 0033-3158</identifier><identifier>EISSN: 1432-2072</identifier><identifier>DOI: 10.1007/s00213-022-06164-y</identifier><identifier>PMID: 35612654</identifier><language>eng</language><publisher>Berlin/Heidelberg: Springer Berlin Heidelberg</publisher><subject>Acute effects ; Adult ; Biomedical and Life Sciences ; Biomedicine ; Brain ; Cannabis ; Double-Blind Method ; Dronabinol - pharmacology ; EEG ; Electroencephalography ; Event-related potentials ; Evoked Potentials - physiology ; Feedback ; Humans ; Motivation ; Neurosciences ; Original Investigation ; Pharmacology/Toxicology ; Placebos ; Psychiatry ; Punishment ; Reaction Time ; Reinforcement ; Reward ; Tetrahydrocannabinol ; THC</subject><ispartof>Psychopharmacology, 2022-09, Vol.239 (9), p.2829-2840</ispartof><rights>The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature 2022</rights><rights>2022. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.</rights><rights>The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature 2022.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c431t-98e89b91183e8f69147c32e1d048b6ca843ed6e3e1341ebb16ba672404fad4463</citedby><cites>FETCH-LOGICAL-c431t-98e89b91183e8f69147c32e1d048b6ca843ed6e3e1341ebb16ba672404fad4463</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s00213-022-06164-y$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s00213-022-06164-y$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>230,314,780,784,885,27924,27925,41488,42557,51319</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/35612654$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Murray, Conor H.</creatorcontrib><creatorcontrib>Glazer, James E.</creatorcontrib><creatorcontrib>Lee, Royce</creatorcontrib><creatorcontrib>Nusslock, Robin</creatorcontrib><creatorcontrib>de Wit, Harriet</creatorcontrib><title>Δ9-THC reduces reward-related brain activity in healthy adults</title><title>Psychopharmacology</title><addtitle>Psychopharmacology</addtitle><addtitle>Psychopharmacology (Berl)</addtitle><description>Rationale Greater availability of cannabis in the USA has raised concerns about adverse effects of the drug, including possible amotivational states. Lack of motivation may be assessed by examining acute effects of cannabinoids on reward processing. Objectives This study examined single doses of delta-9-tetrahydrocannabinol (∆9-THC; 7.5, 15 mg oral) in healthy adults using a version of the monetary incentive delay (MID) task adapted for electroencephalography (EEG; e-MID) in a within-subjects, double blind design. Methods Two phases of reward processing were examined: anticipation, which occurs with presentation of cues that indicate upcoming reward, punishment, or neutral conditions, and outcome, which occurs with feedback indicating hits or misses. During anticipation, we measured two event-related potential (ERP) components: the P300, which measures attention and motivation, and the LPP, which measures affective processing. During outcome processing, we measured P300 and LPP, as well as the RewP, which measures outcome evaluation. Results We found that ∆9-THC modulated outcome processing, but not reward anticipation. Specifically, both doses of ∆9-THC (7.5 and 15 mg) reduced RewP amplitudes after outcome feedback (hits and misses) relative to placebo. ∆9-THC (15 mg) also reduced P300 and LPP amplitudes following hits compared to misses, relative to both placebo and 7.5 mg ∆9-THC. Conclusions These findings suggest that ∆9-THC dampens responses to both reward and loss feedback, which may reflect an “amotivational” state. Future studies are needed to determine generalizability of this effect, such as its pharmacological specificity and its specificity to monetary vs other types of reward.</description><subject>Acute effects</subject><subject>Adult</subject><subject>Biomedical and Life Sciences</subject><subject>Biomedicine</subject><subject>Brain</subject><subject>Cannabis</subject><subject>Double-Blind Method</subject><subject>Dronabinol - pharmacology</subject><subject>EEG</subject><subject>Electroencephalography</subject><subject>Event-related potentials</subject><subject>Evoked Potentials - physiology</subject><subject>Feedback</subject><subject>Humans</subject><subject>Motivation</subject><subject>Neurosciences</subject><subject>Original Investigation</subject><subject>Pharmacology/Toxicology</subject><subject>Placebos</subject><subject>Psychiatry</subject><subject>Punishment</subject><subject>Reaction Time</subject><subject>Reinforcement</subject><subject>Reward</subject><subject>Tetrahydrocannabinol</subject><subject>THC</subject><issn>0033-3158</issn><issn>1432-2072</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><recordid>eNp9kU1u2zAQhYkiRe38XKCLQEA23bCZISmKWgWBkSYFDGTjrglKGscyZMkhpQS6R86VM5WuU7fpotwMgfnmzRs8xj4jfEWA7DIACJQchOCgUSs-fmBTVFJwAZk4YlMAKbnE1EzYcQhriE8Z9YlNZKpR6FRN2dXrS84Xd7PEUzWUFGJ9dr7inhrXU5UU3tVt4sq-fqr7MYn_FbmmX42Jq4amD6fs49I1gc7e6gn78e1mMbvj8_vb77PrOS-VxJ7nhkxe5IhGklnqHFVWSkFYRUOFLp1RkipNklAqpKJAXTidCQVq6SqltDxhV3vd7VBsqCqp7b1r7NbXG-dH27navu-09co-dE8WIdWQmjQqfHlT8N3jQKG3mzqU1DSupW4IVmidpyBklkX04h903Q2-jfdZkYFEk6d6Z0nsqdJ3IXhaHtwg2F1Adh-QjQHZXwHZMQ6d_33HYeR3IhGQeyDEVvtA_s_u_8j-BHXCm6k</recordid><startdate>20220901</startdate><enddate>20220901</enddate><creator>Murray, Conor H.</creator><creator>Glazer, James E.</creator><creator>Lee, Royce</creator><creator>Nusslock, Robin</creator><creator>de Wit, Harriet</creator><general>Springer Berlin Heidelberg</general><general>Springer Nature B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7QG</scope><scope>7QR</scope><scope>7RV</scope><scope>7TK</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>88G</scope><scope>8AO</scope><scope>8FD</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FR3</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>K9.</scope><scope>KB0</scope><scope>M0S</scope><scope>M1P</scope><scope>M2M</scope><scope>NAPCQ</scope><scope>P64</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>PSYQQ</scope><scope>Q9U</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20220901</creationdate><title>Δ9-THC reduces reward-related brain activity in healthy adults</title><author>Murray, Conor H. ; Glazer, James E. ; Lee, Royce ; Nusslock, Robin ; de Wit, Harriet</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c431t-98e89b91183e8f69147c32e1d048b6ca843ed6e3e1341ebb16ba672404fad4463</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>Acute effects</topic><topic>Adult</topic><topic>Biomedical and Life Sciences</topic><topic>Biomedicine</topic><topic>Brain</topic><topic>Cannabis</topic><topic>Double-Blind Method</topic><topic>Dronabinol - pharmacology</topic><topic>EEG</topic><topic>Electroencephalography</topic><topic>Event-related potentials</topic><topic>Evoked Potentials - physiology</topic><topic>Feedback</topic><topic>Humans</topic><topic>Motivation</topic><topic>Neurosciences</topic><topic>Original Investigation</topic><topic>Pharmacology/Toxicology</topic><topic>Placebos</topic><topic>Psychiatry</topic><topic>Punishment</topic><topic>Reaction Time</topic><topic>Reinforcement</topic><topic>Reward</topic><topic>Tetrahydrocannabinol</topic><topic>THC</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Murray, Conor H.</creatorcontrib><creatorcontrib>Glazer, James E.</creatorcontrib><creatorcontrib>Lee, Royce</creatorcontrib><creatorcontrib>Nusslock, Robin</creatorcontrib><creatorcontrib>de Wit, Harriet</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Animal Behavior Abstracts</collection><collection>Chemoreception Abstracts</collection><collection>Nursing &amp; Allied Health Database</collection><collection>Neurosciences Abstracts</collection><collection>Health &amp; Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Psychology Database (Alumni)</collection><collection>ProQuest Pharma Collection</collection><collection>Technology Research Database</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Engineering Research Database</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Nursing &amp; Allied Health Database (Alumni Edition)</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Psychology Database</collection><collection>Nursing &amp; Allied Health Premium</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest One Psychology</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Psychopharmacology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Murray, Conor H.</au><au>Glazer, James E.</au><au>Lee, Royce</au><au>Nusslock, Robin</au><au>de Wit, Harriet</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Δ9-THC reduces reward-related brain activity in healthy adults</atitle><jtitle>Psychopharmacology</jtitle><stitle>Psychopharmacology</stitle><addtitle>Psychopharmacology (Berl)</addtitle><date>2022-09-01</date><risdate>2022</risdate><volume>239</volume><issue>9</issue><spage>2829</spage><epage>2840</epage><pages>2829-2840</pages><issn>0033-3158</issn><eissn>1432-2072</eissn><abstract>Rationale Greater availability of cannabis in the USA has raised concerns about adverse effects of the drug, including possible amotivational states. Lack of motivation may be assessed by examining acute effects of cannabinoids on reward processing. Objectives This study examined single doses of delta-9-tetrahydrocannabinol (∆9-THC; 7.5, 15 mg oral) in healthy adults using a version of the monetary incentive delay (MID) task adapted for electroencephalography (EEG; e-MID) in a within-subjects, double blind design. Methods Two phases of reward processing were examined: anticipation, which occurs with presentation of cues that indicate upcoming reward, punishment, or neutral conditions, and outcome, which occurs with feedback indicating hits or misses. During anticipation, we measured two event-related potential (ERP) components: the P300, which measures attention and motivation, and the LPP, which measures affective processing. During outcome processing, we measured P300 and LPP, as well as the RewP, which measures outcome evaluation. Results We found that ∆9-THC modulated outcome processing, but not reward anticipation. Specifically, both doses of ∆9-THC (7.5 and 15 mg) reduced RewP amplitudes after outcome feedback (hits and misses) relative to placebo. ∆9-THC (15 mg) also reduced P300 and LPP amplitudes following hits compared to misses, relative to both placebo and 7.5 mg ∆9-THC. Conclusions These findings suggest that ∆9-THC dampens responses to both reward and loss feedback, which may reflect an “amotivational” state. Future studies are needed to determine generalizability of this effect, such as its pharmacological specificity and its specificity to monetary vs other types of reward.</abstract><cop>Berlin/Heidelberg</cop><pub>Springer Berlin Heidelberg</pub><pmid>35612654</pmid><doi>10.1007/s00213-022-06164-y</doi><tpages>12</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0033-3158
ispartof Psychopharmacology, 2022-09, Vol.239 (9), p.2829-2840
issn 0033-3158
1432-2072
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_10560585
source MEDLINE; SpringerLink Journals - AutoHoldings
subjects Acute effects
Adult
Biomedical and Life Sciences
Biomedicine
Brain
Cannabis
Double-Blind Method
Dronabinol - pharmacology
EEG
Electroencephalography
Event-related potentials
Evoked Potentials - physiology
Feedback
Humans
Motivation
Neurosciences
Original Investigation
Pharmacology/Toxicology
Placebos
Psychiatry
Punishment
Reaction Time
Reinforcement
Reward
Tetrahydrocannabinol
THC
title Δ9-THC reduces reward-related brain activity in healthy adults
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-06T03%3A33%3A46IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=%CE%949-THC%20reduces%20reward-related%20brain%20activity%20in%20healthy%20adults&rft.jtitle=Psychopharmacology&rft.au=Murray,%20Conor%20H.&rft.date=2022-09-01&rft.volume=239&rft.issue=9&rft.spage=2829&rft.epage=2840&rft.pages=2829-2840&rft.issn=0033-3158&rft.eissn=1432-2072&rft_id=info:doi/10.1007/s00213-022-06164-y&rft_dat=%3Cproquest_pubme%3E2703189566%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2703189566&rft_id=info:pmid/35612654&rfr_iscdi=true